---
figid: PMC2861144__nihms195501f1
figtitle: Novel targets for the treatment of autosomal dominant polycystic kidney
  disease
organisms:
- Mus musculus
- Rattus norvegicus
- Bikinia letestui
- Tripterygium wilfordii
- Homo sapiens
- Canis lupus familiaris
- Streptomyces hygroscopicus
pmcid: PMC2861144
filename: nihms195501f1.jpg
figlink: /pmc/articles/PMC2861144/figure/F1/
number: F1
caption: 'Potential targets for inhibition are depicted in light gray boxes. Potential
  inhibitors are depicted in clear boxes. The cAMP pathway promotes cell proliferation
  and fluid secretion in PKD. cAMP leads to fluid secretion via the CFTR. cAMP results
  in activation of the ERK-MAPK pathway leading to cell proliferation. cAMP accumulation
  is promoted by mechanisms of dysregulation of PC1 or PC2, as well as inhibition
  of Ca2+-dependent phosphodiesterase (PDE). Caffeine inhibits PDE, which normally
  degrades cAMP. Thus, caffeine results in an increase in cAMP. cAMP signaling also
  requires PKA, Src and Ras. Src is known to activate Ras. Activation of tyrosine
  kinase receptors also contributes to the stimulation of MAPK-ERK signaling with
  consequent cell proliferation. Potential therapeutic targets are the vasopressin
  V2 receptor, tyrosine kinases, MEK and c-Src. The PI3K-Akt pathway plays a major
  role in mTOR signaling (see ); mTOR inhibitors bind to FKBP, which subsequently
  inhibits mTOR. There is evidence for activation of the mTOR pathway in ADPKD. The
  RAAS (see ) is activated by a drop in renal perfusion that stimulates the JGA to
  make renin. ACE inhibitors block the conversion of angiotensin I to angiotensin
  II. Renin inhibitors directly block renin production by the JGA. Angiotensin receptor
  blockers block the ATIIR. There is evidence for activation of the RAAS in ADPKD
  patients.ACE: Angiotensin-converting enzyme; AGT1: Angiotensin 1; ARB: Angiotensin
  receptor blocker; ATIIR: Angiotensin II receptor; Ca2+: Intracellular calcium; cAMP:
  Cyclic adenosine monophosphate; CDK: Cyclin-dependent kinase; CFTR: Cystic fibrosis
  transmembrane conductance regulator; EGF: Epidermal growth factor; ERK: Extracellular
  signal-regulated kinase; FKBP: FK506 binding protein; Gi,Gs: G protein; HMG-CoAR:
  3-hydroxy-3-methyl-glutaryl-CoA reductase; IGF: Insulin-like growth factor; JGA:
  Juxtaglomerular apparatus; MAPK: Mitogen–activated protein kinase; MEK: Maperk kinase;
  mTOR: Mammalian target of rapamycin; PI3K: Phosphoinositide 3-kinase; PC1: Polycystin1;
  PC2: Polycystin2; PDE: Phosphodiesterase; PKA: Protein kinase A; Rheb: Ras homolog
  enriched in brain; Src: Sarcoma; SSTR: Somatostatin receptor; TKI: Tyrosine kinase
  inhibitor; TNF: Tumor necrosis factor; V2R: Vasopressin v2 receptor; VEGF: Vascular
  endothelial growth factor.'
papertitle: Novel targets for the treatment of autosomal dominant polycystic kidney
  disease.
reftext: Franck A Belibi, et al. Expert Opin Investig Drugs. ;19(3):315-328.
year: ''
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9648557
figid_alias: PMC2861144__F1
figtype: Figure
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Canis lupus familiaris
- Homo sapiens
redirect_from: /figures/PMC2861144__F1
ndex: d2c5deba-ded3-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC2861144__nihms195501f1.html
  '@type': Dataset
  description: 'Potential targets for inhibition are depicted in light gray boxes.
    Potential inhibitors are depicted in clear boxes. The cAMP pathway promotes cell
    proliferation and fluid secretion in PKD. cAMP leads to fluid secretion via the
    CFTR. cAMP results in activation of the ERK-MAPK pathway leading to cell proliferation.
    cAMP accumulation is promoted by mechanisms of dysregulation of PC1 or PC2, as
    well as inhibition of Ca2+-dependent phosphodiesterase (PDE). Caffeine inhibits
    PDE, which normally degrades cAMP. Thus, caffeine results in an increase in cAMP.
    cAMP signaling also requires PKA, Src and Ras. Src is known to activate Ras. Activation
    of tyrosine kinase receptors also contributes to the stimulation of MAPK-ERK signaling
    with consequent cell proliferation. Potential therapeutic targets are the vasopressin
    V2 receptor, tyrosine kinases, MEK and c-Src. The PI3K-Akt pathway plays a major
    role in mTOR signaling (see ); mTOR inhibitors bind to FKBP, which subsequently
    inhibits mTOR. There is evidence for activation of the mTOR pathway in ADPKD.
    The RAAS (see ) is activated by a drop in renal perfusion that stimulates the
    JGA to make renin. ACE inhibitors block the conversion of angiotensin I to angiotensin
    II. Renin inhibitors directly block renin production by the JGA. Angiotensin receptor
    blockers block the ATIIR. There is evidence for activation of the RAAS in ADPKD
    patients.ACE: Angiotensin-converting enzyme; AGT1: Angiotensin 1; ARB: Angiotensin
    receptor blocker; ATIIR: Angiotensin II receptor; Ca2+: Intracellular calcium;
    cAMP: Cyclic adenosine monophosphate; CDK: Cyclin-dependent kinase; CFTR: Cystic
    fibrosis transmembrane conductance regulator; EGF: Epidermal growth factor; ERK:
    Extracellular signal-regulated kinase; FKBP: FK506 binding protein; Gi,Gs: G protein;
    HMG-CoAR: 3-hydroxy-3-methyl-glutaryl-CoA reductase; IGF: Insulin-like growth
    factor; JGA: Juxtaglomerular apparatus; MAPK: Mitogen–activated protein kinase;
    MEK: Maperk kinase; mTOR: Mammalian target of rapamycin; PI3K: Phosphoinositide
    3-kinase; PC1: Polycystin1; PC2: Polycystin2; PDE: Phosphodiesterase; PKA: Protein
    kinase A; Rheb: Ras homolog enriched in brain; Src: Sarcoma; SSTR: Somatostatin
    receptor; TKI: Tyrosine kinase inhibitor; TNF: Tumor necrosis factor; V2R: Vasopressin
    v2 receptor; VEGF: Vascular endothelial growth factor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Vegfa
  - Igf1
  - Egf
  - Avpr2
  - Mdk
  - gs
  - Gs
  - Braf
  - ras
  - Hras
  - Kras
  - Rem1
  - Src
  - Twist1
  - Tnf
  - Cftr
  - Myc
  - Nol3
  - Jun
  - Ephb2
  - Mapk1
  - Akt1
  - Tsc1
  - Rps6kb1
  - Tsc2
  - pk
  - Mtor
  - Rheb
  - Ms6hm
  - Pcsk1
  - Enpp1
  - Pkd1
  - Fkbp1a
  - Cbx4
  - Pcsk2
  - Pkd2
  - Ms6hm3
  - Hmgcr
  - Ace
  - Agtrap
  - Tmprss5
  - Sstr3
  - Ephb1
  - Agtr1a
  - Agxt2
  - VEGFA
  - IGF1
  - EGF
  - BRAF
  - SRC
  - TNF
  - CFTR
  - MYC
  - JUN
  - TSC1
  - TSC2
  - MTOR
  - RHEB
  - PCSK1
  - PKD1
  - PKD2
  - ACE
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - AVPR2
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - APRT
  - MFAP1
  - GNAS
  - GNAL
  - KRAS
  - HRAS
  - NRAS
  - FGR
  - FYN
  - YES1
  - ALDH7A1
  - PDE2A
  - PDE9A
  - PDE10A
  - PDE11A
  - PDE1A
  - PDE1B
  - PDE1C
  - PDE3A
  - PDE3B
  - PDE4A
  - PDE4B
  - PDE4C
  - PDE4D
  - PDE6A
  - PDE6B
  - PDE6C
  - PDE7A
  - PDE7B
  - PDE8A
  - PDE8B
  - GNAO1
  - GNAI1
  - GNAI2
  - GNAI3
  - GNAT1
  - GNAT2
  - GNAT3
  - GNAZ
  - JUNB
  - JUND
  - CCND1
  - CCND2
  - CCND3
  - EPHB2
  - MAPK1
  - MAPK3
  - CDKL1
  - CDKL2
  - CDKL3
  - CDKL4
  - CDKL5
  - CDK3
  - CDK4
  - CDK5
  - CDK6
  - CDK7
  - CDK8
  - CDK9
  - CDK10
  - CDK11A
  - CDK11B
  - CDK12
  - CDK13
  - CDK14
  - CDK15
  - CDK16
  - CDK17
  - CDK18
  - CDK19
  - CDK20
  - CDK1
  - CDK2
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - AKT1
  - AKT2
  - AKT3
  - CCL26
  - RPS6KB1
  - RPS6KB2
  - RHEBP1
  - KRT16
  - ENPP1
  - TPD52
  - KRT6B
  - KRT17
  - PCSK2
  - CBX4
  - BEST1
  - AGTR1
  - ASIP
  - AGXT2
  - Triptolide
  - aliskiren
  - Caffeine
  - Chloride
  - losartan
  - Cancer
  - Melanoma
---
